Early signs of disease in type 1 diabetes

dc.contributor.authorRobert Moulder
dc.contributor.authorRiitta Lahesmaa
dc.contributor.organizationfi=Turun biotiedekeskus|en=Turku Bioscience Centre|
dc.contributor.organization-code1.2.246.10.2458963.20.18586209670
dc.converis.publication-id16896487
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/16896487
dc.date.accessioned2022-10-28T13:39:28Z
dc.date.available2022-10-28T13:39:28Z
dc.description.abstract<p>As a severe chronic disease with long-term complications, type 1 diabetes (T1D) is a burden to the patients and their families as well as a challenge to the health care system. T1D is a heterogeneous disease with a variety of etiologies and a wide range in the rate of progression to the disease. In order to prevent and treat T1D it would be important to identify measures that could be used to predict and monitor disease progression, as well as to further understand the molecular mechanisms involved. During the past 20 yr since its initiation, the Finnish Diabetes Prediction and Prevention Project (DIPP) has collected longitudinal biological samples from children with a human leukocyte antigen gene-conferred risk of T1D. This large sample collection has provided detailed sample series that enable studies to map the progression from health to disease, as well as the healthy maturation of risk-matched children. The DIPP samples have been used in a large body of research to elucidate the factors involved in the development of T1D. Interestingly, results from recent studies exploiting omics platforms have revealed that signs of the disease process can be detected very early on, even prior to appearance of the first T1D-associated antibodies, which are currently considered the earliest indications of the emerging disease. Identification and validation of multi-modal molecular markers will we hope provide a means to subgroup the heterogeneous group of T1D patients and enable prediction, diagnosis, and monitoring of T1D. Discovery of such markers is important in the design and testing of prevention and therapies for T1D</p>
dc.format.pagerange43
dc.format.pagerange48
dc.identifier.eissn1399-5448
dc.identifier.jour-issn1399-543X
dc.identifier.olddbid183417
dc.identifier.oldhandle10024/166511
dc.identifier.urihttps://www.utupub.fi/handle/11111/29172
dc.identifier.urnURN:NBN:fi-fe2021042715515
dc.okm.affiliatedauthorMoulder, Robert
dc.okm.affiliatedauthorLahesmaa, Riitta
dc.okm.discipline318 Medical biotechnologyen_GB
dc.okm.discipline318 Lääketieteen bioteknologiafi_FI
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA2 Scientific Article
dc.publisherWiley
dc.relation.doi10.1111/pedi.12329
dc.relation.ispartofjournalPediatric Diabetes
dc.relation.issueSuppl. 22
dc.relation.volume17
dc.source.identifierhttps://www.utupub.fi/handle/10024/166511
dc.titleEarly signs of disease in type 1 diabetes
dc.year.issued2016

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
Early_Signs_of _T1D_ArchiveDoc_preref.pdf
Size:
62.64 KB
Format:
Adobe Portable Document Format